RedHill's Opaganib Shows Positive Preclinical Results in Neuroblastoma and Triple-Negative Breast Cancer
RDHL sits 21% above its 52-week low of $0.71.
Summary
RedHill Biopharma announced positive preclinical data for its drug candidate Opaganib in neuroblastoma and triple-negative breast cancer, suggesting enhanced chemotherapy efficacy and anti-tumor immunity.
Key Events · Product Development and Regulatory · RDHL
-
Positive Preclinical Data
Opaganib showed positive effects as an add-on therapy in models of neuroblastoma (NB) and triple-negative breast cancer (TNBC) at the AACR 2026 Annual Meeting.
-
Enhanced Chemotherapy Efficacy
In neuroblastoma, Opaganib enhanced the therapeutic efficacy of the oxaliplatin + doxorubicin chemotherapy combination by directly destabilizing n-Myc.
-
Augmented Anti-Tumor Immunity
In triple-negative breast cancer, Opaganib pre-treatment potentiated STING-mediated effects, potentially augmenting anti-tumor immunity.
-
Orphan Drug Designation
Opaganib holds FDA Orphan Drug and Rare Pediatric Disease designations for the treatment of neuroblastoma.
Analysis · RDHL · Life Sciences
This filing provides positive preclinical data for Opaganib, a key pipeline asset, in two difficult-to-treat cancers. While preclinical, these results offer a potential long-term value driver and a positive development amidst the company's recent Nasdaq delisting notice. The data suggests Opaganib could enhance chemotherapy efficacy and augment anti-tumor immunity, supporting its continued development and potential for an Orphan Drug Priority Review Voucher.
At the time of this filing, RDHL was trading at $0.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.71 to $3.31. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.